tumor mutational burden
Precision Oncology in 2021: Growing Complexity, Refining Liquid Biopsy Use, Focus on Access Gaps
Amid new treatment options and a growing list of actionable biomarkers, the field last year also focused on the need to better support oncologists and address access gaps for patients.
Top 10 Precision Oncology Articles in 2021: Liquid Biopsy, Difficult Reimbursement, TMB Debates
Five out of the 10 most read stories this year dealt with liquid biopsy testing to detect cancer or guide therapy decisions.
Survey of Precision Oncology Programs Shows Rapid Pace of Advances a Major Challenge for Oncologists
Results from Precision Oncology News' survey indicate that keeping up with the fast-changing treatment landscape has overtaken reimbursement as the top challenge for doctors.
A multiomic study out of TGen and the Beat Childhood Cancer Research Consortium found potentially actionable tumor changes at the point of disease relapse.
Recent studies in NSCLC, melanoma, and breast cancer suggest that major histocompatibility complex expression could guide checkpoint inhibitor selection.